Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab

Status:	Active, not recruiting
Conditions:	Blood Cancer, Hematology
Therapuetic Areas:	Hematology, Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	1/16/2019
Start Date:	July 11, 2016
End Date:	May 29, 2020

The purpose of this study is to continue to provide elotuzumab and/or other study drugs to
subjects who have participated on a prior protocol investigating elotuzumab who are not able
to receive commercial drug supply.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Participated in a previous elotuzumab protocol (including, but not limited to
HuLuc63-1703, CA204007, CA204009, or CA204011) and is deemed by the investigator to be
deriving benefit from elotuzumab and/or other study drugs as defined by the previous
protocol

- Receiving elotuzumab and/or other study drugs at the time of signature of informed
consent

- Males and Females, ages 18 and older

Exclusion Criteria:

- All subjects previously discontinued from an elotuzumab study for any reason

- Subjects not receiving clinical benefit from previous study therapy

- Subjects who are not medically well enough to receive study therapy as determined by
the investigator

Other protocol defined inclusion/exclusion criteria could apply

We found this trial at

sites

James R. Berenson, MD, Inc.

Bakersfield, California 93309

from

Bakersfield, CA